<code id='3330766401'></code><style id='3330766401'></style>
    • <acronym id='3330766401'></acronym>
      <center id='3330766401'><center id='3330766401'><tfoot id='3330766401'></tfoot></center><abbr id='3330766401'><dir id='3330766401'><tfoot id='3330766401'></tfoot><noframes id='3330766401'>

    • <optgroup id='3330766401'><strike id='3330766401'><sup id='3330766401'></sup></strike><code id='3330766401'></code></optgroup>
        1. <b id='3330766401'><label id='3330766401'><select id='3330766401'><dt id='3330766401'><span id='3330766401'></span></dt></select></label></b><u id='3330766401'></u>
          <i id='3330766401'><strike id='3330766401'><tt id='3330766401'><pre id='3330766401'></pre></tt></strike></i>

          knowledge

          knowledge

          author:focus    Page View:7989
          Judge's gavel
          Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

          WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

          Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

          advertisement

          Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024
          JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

          EricTokatisco-presidentofinvestmentbankingatCenterviewPartners.CourtesyCenterviewPartnersSANFRANCISC

          read more
          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more

          Kenai launches with $82 million for Parkinson’s stem cell therapy

          AdobeThedreamofbeingabletopluckacelltherapyoffofafreezershelfandspeedilygiveittocancerpatientsismate